These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 19887868)

  • 1. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
    Goerner M; Riemer-Hommel P
    Onkologie; 2009 Nov; 32(11):647-52. PubMed ID: 19887868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
    Douillard JY; Tilleul P; Ychou M; Dufour P; Perrocheau G; Seitz JF; Maes P; Lafuma A; Husseini F
    Oncology; 2007; 72(3-4):248-54. PubMed ID: 18185019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant chemotherapy for colon cancer].
    Dahl O
    Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Grothey A; Kleeberg UR; Stauch M; Hieke K
    Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant therapy of colon carcinoma].
    Trarbach T; Kubicka S; Hacker U; Ridwelski K; Reinacher-Schick A
    Onkologie; 2008; 31 Suppl 5():19-23. PubMed ID: 19033700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted agents for adjuvant therapy of colon cancer.
    de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
    Semin Oncol; 2006 Dec; 33(6 Suppl 11):S42-5. PubMed ID: 17178286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and challenges in the adjuvant treatment of stage II and III colon cancers.
    Chua YJ; Zalcberg JR
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):595-604. PubMed ID: 18402526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world resource use and costs of adjuvant treatment for stage III colon cancer.
    van Gils CW; de Groot S; Tan SS; Redekop WK; Koopman M; Punt CJ; Uyl-de Groot CA
    Eur J Cancer Care (Engl); 2015 May; 24(3):321-32. PubMed ID: 24372941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
    Benson AB
    Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival.
    Samantas E; Dervenis C; Rigatos SK
    Dig Dis; 2007; 25(1):67-75. PubMed ID: 17384510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy for colon cancer: present and perspectives.
    De Dosso S; Sessa C; Saletti P
    Cancer Treat Rev; 2009 Apr; 35(2):160-6. PubMed ID: 19013023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
    Prescrire Int; 2006 Jun; 15(83):109-1. PubMed ID: 16764102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy of stage III colon cancer.
    Benson AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S74-7. PubMed ID: 16399437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of colonic carcinoma in the year 2001].
    Mross K; Semsek D
    Praxis (Bern 1994); 2001 Mar; 90(12):497-510. PubMed ID: 11324309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
    Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.